Vitamin D up-regulates the vitamin D receptor by protecting it from proteasomal degradation in human CD4+ T cells

PLoS One. 2014 May 2;9(5):e96695. doi: 10.1371/journal.pone.0096695. eCollection 2014.

Abstract

The active form of vitamin D3, 1,25(OH)2D3, has significant immunomodulatory properties and is an important determinant in the differentiation of CD4+ effector T cells. The biological actions of 1,25(OH)2D3 are mediated by the vitamin D receptor (VDR) and are believed to correlate with the VDR protein expression level in a given cell. The aim of this study was to determine if and how 1,25(OH)2D3 by itself regulates VDR expression in human CD4+ T cells. We found that activated CD4+ T cells have the capacity to convert the inactive 25(OH)D3 to the active 1,25(OH)2D3 that subsequently up-regulates VDR protein expression approximately 2-fold. 1,25(OH)2D3 does not increase VDR mRNA expression but increases the half-life of the VDR protein in activated CD4+ T cells. Furthermore, 1,25(OH)2D3 induces a significant intracellular redistribution of the VDR. We show that 1,25(OH)2D3 stabilizes the VDR by protecting it from proteasomal degradation. Finally, we demonstrate that proteasome inhibition leads to up-regulation of VDR protein expression and increases 1,25(OH)2D3-induced gene activation. In conclusion, our study shows that activated CD4+ T cells can produce 1,25(OH)2D3, and that 1,25(OH)2D3 induces a 2-fold up-regulation of the VDR protein expression in activated CD4+ T cells by protecting the VDR against proteasomal degradation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology
  • CD4 Antigens / immunology*
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • Calcitriol / immunology*
  • Cells, Cultured
  • Cytochrome P-450 CYP3A Inhibitors / pharmacology
  • Fatty Acids, Unsaturated / pharmacology
  • Humans
  • Ketoconazole / pharmacology
  • Lymphocyte Activation
  • Proteasome Endopeptidase Complex / immunology
  • Proteasome Endopeptidase Complex / metabolism*
  • Proteasome Inhibitors / pharmacology
  • Protein Transport / drug effects
  • Proteolysis / drug effects
  • Receptors, Calcitriol / genetics
  • Receptors, Calcitriol / immunology
  • Receptors, Calcitriol / metabolism*
  • Up-Regulation / drug effects

Substances

  • Antifungal Agents
  • CD4 Antigens
  • Cytochrome P-450 CYP3A Inhibitors
  • Fatty Acids, Unsaturated
  • Proteasome Inhibitors
  • Receptors, Calcitriol
  • Proteasome Endopeptidase Complex
  • Calcitriol
  • Ketoconazole
  • leptomycin B

Grants and funding

This work was supported by grants from The Danish Medical Research Council, The Lundbeck Foundation, The Novo Nordisk Foundation, and The A.P. Møller Foundation for the Advancement of Medical Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.